On February 20, 2025, Immunic, Inc. reported positive results from a post-hoc analysis of its phase 1b clinical trial of IMU-856 in celiac disease, showing increased GLP-1 levels and reduced body weight gain in preclinical studies. The company will discuss these findings in a webinar and at a congress on the same day.